Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00449761
Other study ID # CLBH589B2211
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date February 23, 2007
Est. completion date August 26, 2008

Study information

Verified date July 2021
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic myeloid leukemia who are in accelerated phase or blast phase (blast crisis) with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors


Description:

study was designed to assess the hematologic response associated with treatment of oral panobinostat. Hematologic response is defined as the overall of complete hematologic response (CHR), and of no evidence of leukemia (NEL) and of the return to chronic phase (RTC). Hematologic responses were to be confirmed after 4 weeks, and all criteria listed below for each type of response were to be concomitantly met to result into a response.


Recruitment information / eligibility

Status Terminated
Enrollment 27
Est. completion date August 26, 2008
Est. primary completion date January 29, 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Male or female patients aged = 18 years old - Diagnosis of Philadelphia chromosome positive accelerated or blast phase chronic myeloid leukemia defined as: Accelerated phase - the presence of at least one of the following: - =15% but <30% blasts in blood or bone marrow - =30% blasts plus promyelocytes in peripheral blood or bone marrow (providing that <30% blasts present in bone marrow) - = 20% basophiles in the peripheral blood - Thrombocytopenia <100 X 109 /L unrelated to sole therapy Blast phase (blast crisis) - the presence of one of the following: - = 30% blasts in the blood, in bone marrow or both - Extramedullary infiltrates of leukemic cells other than liver or spleen involvement - Prior treatment with at least two a fusion gene of the BCR and ABL genes (BCR-ABL) tyrosine kinase inhibitors (i.e., imatinib, nilotinib, or dasatinib) and demonstrated resistance to the most recent kinase inhibitor therapy. Resistance to a BCR-ABL tyrosine kinase inhibitors (TKI) for this study was defined as: - Progression from chronic phase to either accelerated phase or blast crisis - Progression from accelerated phase to blast crisis - No hematologic response (defined as not achieving complete hematologic response (CHR), no evidence of leukemia (NEL) or return to chronic phase (RTC)) within 3 months of starting therapy - Increasing blast counts in peripheral blood of increasing marrow leukemic infiltrate (MLI, the percent marrow blasts multiplied by marrow cellularity) - Patients with a history of intolerance to one BCR-ABL kinase inhibitors (defined as discontinuation of treatment due grade 3 or 4 adverse events related to treatment) will be considered eligible to enter the study if they demonstrate resistance to their most recent BCR-ABL kinase inhibitor. Intolerance was defined as discontinuation of treatment due to either grade 3 or 4 treatment-related Adverse Event (AE) or a grade 2 treatment-related AE persisting for = one month or recurring more than three times despite dose reduction. - Patients must have adequate laboratory values: - Serum albumin = 3g/dL - Aspartate Aminotransferase (AST)/Serum Glutamate Oxalacetate Transaminase (SGOT) and Alanine Aminotransferase (ALT)/Serum Glutamate Pyruvate Transaminase (SGPT) = 2.5 x upper limit of normal (ULN) or = 5.0 x ULN if the transaminase elevation is due to leukemic involvement - Serum bilirubin = 1.5 x ULN - Serum creatinine = 1.5 x ULN or 24-hour creatinine clearance = 50 ml/min - Serum potassium, phosphorus, magnesium, and serum total calcium (corrected for serum albumin) or serum ionized calcium = Lower Limit of Normal (LLN). Supplementation was allowed to correct potassium, calcium, and magnesium values prior to enrollment. - Thyroid Stimulating Hormone (TSH) and free Thyroxine (T4) within normal limits (WNL) (patients may have been on thyroid hormone replacement) - Baseline measurement of left ventricular ejection fraction [assessment of the hearts ability to pump effectively] - Assessment of patients ability to perform every day activities. Assessment by the Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2. Exclusion criteria: - A candidate for hematopoietic stem cell transplantation - Prior therapy with certain medications: - Therapeutic doses of sodium warfarin or any other anti-vitamin K drug (low doses for line patency were allowed). - Candidate for hematopoietic stem cell transplantation (HSCT) - Prior histone deacetylase (HDAC) inhibitor treatment of Chronic Myelogenous Leukemia (CML) - Concomitant use of drugs with a risk of causing QT complex (QTc) prolongation or torsades de pointes, CYP3A4/5 inhibitors, anti-cancer therapy or radiation therapy, valproic acid (within 5 days prior to study drug treatment or during the study), chemotherapy (within 3 weeks), immunotherapy (within 1 week), BCR-ABL kinase inhibitor = 1 week of first treatment with panobinostat - Patients who are in chronic phase chronic myeloid leukemia - Impaired cardiac function or clinically significant cardiac diseases - Concomitant use of drugs with a risk of possible risk of causing QTc prolongation or torsades de pointes - Concomitant use of certain medications - Impairment of Gastrointestinal (GI) function or GI disease - Patients with unresolved diarrhea - Women who are pregnant or breast feeding or women of childbearing potential not using an effective method of birth control - Male patients whose sexual partners are women of child bearing potential not using effective birth control Other protocol-defined inclusion/exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LBH589


Locations

Country Name City State
Germany Novartis Investigative Site Cologne
Germany Novartis Investigative Site Duesseldorf
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Mainz
Germany Novartis Investigative Site Mannheim
Germany Novartis Investigative Site Munich
United States University of Michigan Ann Arbor Michigan
United States University of Colorado Health Sciences Center/Anschutz Cancer Pavilion Aurora Colorado
United States Indiana Blood and Marrow Institute/St. Francis Hospital Beech Grove Indiana
United States Roswell Park Cancer Institute Buffalo New York
United States Northwestern University Clinical Research Office Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States University Chicago Hospital Chicago Illinois
United States University of Texas Southwestern Medical Center Dallas Texas
United States Rocky Mountain Cancer Center Denver Colorado
United States City of Hope National Medical Center Duarte California
United States Duke University Hospital Durham North Carolina
United States Hackensack University Medical Center/Oncology Research Dept. Hackensack New Jersey
United States Emory University School of Medicine-Winship Cancer Institute Nashville Tennessee
United States Vanderbilt University Medical Center, Clinical Trials Center Nashville Tennessee
United States Oregon Health & Science University Portland Oregon
United States Mayo Clinic Cancer Center Rochester Minnesota
United States University of Rochester Medical Center Rochester New York
United States Seattle Cancer Care Alliance Seattle Washington
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Germany, 

References & Publications (1)

Savelieva M, Woo MM, Schran H, Mu S, Nedelman J, Capdeville R. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. Eur J Clin Pharmacol. 2015 Jun;71(6):663-672. doi: 10.1007/s00228-015-1846-7. Ep — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Participants With Hematologic Response The primary efficacy variable was hematologic response, a composite endpoint defined as the overall of complete hematologic response (CHR), and of no evidence of leukemia (NEL) and of the return to chronic phase (RTC). From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Duration of Hematologic Response Duration of hematologic response is defined as the time from the first documentation of the hematologic response to the date of the first documentation of the disease progression From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Complete Cytogenetic Response (CCyR) Rate Durations of complete cytogenetic response is defined as the time from the first documentation of the major/complete response to the first documentation of the disease progression. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Major (Complete/Partial) Cytogenetic Response Rate Durations of major/complete cytogenetic response is defined as the time from the first documentation of the major/complete response to the first documentation of the disease progression. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Complete Cytogenetic Response (CCyR) and Overall (Complete/Partial/Minor/Minimal) Cytogenetic Response (OCyR) Rates Cytogenetic response was assessed by bone marrow assessment based on the percentage of Ph+ metaphases by karyotype analysis on a bone marrow aspirate, was ideally assessed from a minimum of 20 metaphases in each bone marrow sample. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Duration of Major Cytogenetic Response The duration of response was defined as the time between the first documented response to the date of discontinuation due to progressive disease (PD) or death. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Major (MMR) and Complete (CMR) Molecular Response Rates Molecular response was defined as major (= 0.1% on the International Scale) and complete [absence of fusion gene of the BCR and ABL genes (BCR-ABL) on an quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay with a sensitivity of at least 4.5 logs below baseline]. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary BCR-ABL Mutations of Participants at Study Entry and, in Responding Participants and at the Time of Disease Progression A fusion gene of the BCR and ABL genes (BCR-ABL) messenger ribose nucleic acid (mRNA) expression (molecular response) was performed by quantitative polymerase chain reaction (qPCR) and mutational analysis was performed by direct sequencing technology, and both analyses were performed by Genzyme. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Progression Free Survival (PFS) Progressions free survival is defined as time between Day 1 cycle 1 and time to first documented disease progression or death. Disease progression will be determined as per response criteria. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Overall Survival Time Overall survival time is defined as the time from the treatment start to the date of death due to any reason. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Time to Peak Concentration (Tmax) of Panobinostat Tmax is defined as the time at which the Cmax occurs. It will be obtained from the Tmax parameter calculated by WinNonlin®. If there is no measurable Cmax in the subject's Pharmacokinetic (PK) profile, then Tmax will be missing for that subject. Tmax will be reported in units of h. Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary Maximum Plasma Concentration (Cmax) of Panobinostat Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations. It will be obtained from the Cmax parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Cmax will be missing for that subject. Cmax will be reported in units of ng/mL. Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary Area Under the Plasma Concentration (AUC0-24) of Panobinostat Area under the curve (AUC) is defined as the area under concentration-time curve as a measure of drug exposure. The area under the plasma concentration-time curve from time zero to 24 hours. Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary Last Observed Plasma Concentration (Clast) of Panobinostat Clast is defined as the Last observed (quantifiable) plasma concentration (Clast), in units of ng/mL. Blood samples were collected to assess Clast. Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary Time of Clast (Tlast) of Panobinostat Time of Clast (Tlast) will be obtained from the Tlast parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Tlast will be missing for that participants. Tlast will be reported in units of h. Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary QT Interval (QTc) in Participants Receiving Oral Panobinostat at Baseline and Change From Baseline to Extreme Value QTc monitoring was performed on specified days (Cycle1: Day1, 5 and 26), as well as a single pre-dose ECG once weekly during Cycle1: Week2 and Week3, Cycle2, and all subsequent cycles. Patient eligibility was ensured by a screening QTcF interval calculated by eResearchTechnology(eRT) prior to the baseline assessments. Treatment decisions were based on QTc determined by the automated reading at the investigational site (commonly used the Bazett's correction,QTcB) or measured and calculated by trained personnel at the site. Dosing relied on the investigator's assessment of the 6 baseline ECGs (the average of the 6pre-dose QTc intervals) performed prior to Cycle1/Day1 dosing, of the 3pre-dose ECGs during Cycle1:Day5 and 26, and of the single pre-dose ECGs performed once weekly for the remaining weeks of Cycle1 and subsequent cycles. The Baseline and Change From Baseline to Extreme Value QTcF interval for analysis was calculated by eRT based on the 6 baseline ECGs obtained on Cycle1/Day1. From Start of the Study up to Study Termination (approximately up to 18 Months).
Secondary Safety and Tolerability of Panobinostat Adverse Events (AE) are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards From Start of the Study up to Study Termination (approximately up to 18 Months).
See also
  Status Clinical Trial Phase
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Completed NCT00759837 - Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects Phase 1
Completed NCT00538109 - An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase N/A
Completed NCT00040105 - Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia Phase 1
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Recruiting NCT01015742 - Unrelated Double Umbilical Cord Blood Units Transplantation Phase 2/Phase 3
Completed NCT00406393 - Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Phase 3
Completed NCT00246662 - Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies Phase 1
Completed NCT00264160 - Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy Phase 2/Phase 3
Terminated NCT00306332 - T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Phase 3
Terminated NCT00058747 - AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ Phase 2
Active, not recruiting NCT00538447 - Prospective Database for Chronic Myelogenous Leukemia N/A
Terminated NCT01050946 - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Phase 2
Completed NCT00034684 - Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) Phase 1/Phase 2
Recruiting NCT04260022 - Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Phase 1
Terminated NCT00167180 - Post Transplant Donor Lymphocyte Infusion Phase 2
Completed NCT00455221 - Safety Assessment of a Multipeptide-gene Vaccine in CML Phase 1
Completed NCT00298987 - A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate Phase 2
Completed NCT00763763 - Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive Phase 2